edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.
Kazia Therapeutics — 9 videos in collection
In the second part of this three-episode Edison TV series, Kazia Therapeutics (KZIA), dives deeper into paxalisib for additional indications beyond glioblastoma. These indications include DIPG, a highly aggressive childhood brain cancer, primary CNS lymphoma, and brain metastases.
John Friend, CMO, discusses ongoing investigator-initiated trials and collaborations. James Garner, CEO, addresses commercialisation plans.
Get access to the very latest content matched to your personal investment style.